KISIMA-02 vaccine-based immunotherapy

KISIMA-02 vaccine-based immunotherapy · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KISIMA-02 vaccine-based immunotherapy, covering 2026-04-01 to 2026-04-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer [Phase 1]